Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2744055 | 0.86 | EPHX2 (0.43) | OPRM1OPRK1 | |
| SCHEMBL2744099 | 0.83 | OPRM1 (0.39) | KDM4EDRD2DRD4DRD3OPRM1 | |
| SCHEMBL2743769 | 0.82 | NCF1 (0.45) | KDM4EKMT2AMEN1POLBDRD2 | |
| SCHEMBL2744820 | 0.82 | OPRM1 (0.41) | KDM4EHTTMAPTKMT2AMEN1 | |
| SCHEMBL2744509 | 0.82 | OPRM1 (0.63) | KDM4EALOX15HTTMAPTKMT2A | |
| SCHEMBL2429798 | 0.82 | EPHX2 (0.46) | — | |
| SCHEMBL2744862 | 0.81 | HRH3 (0.52) | MAPTOPRM1OPRK1TSHRALDH1A1 | |
| SCHEMBL2744540 | 0.80 | OPRM1 (0.43) | KDM4EHTTKMT2AMEN1POLB | |
| SCHEMBL2744070 | 0.80 | KDM4E (0.50) | KDM4EMAPTKMT2ADRD2DRD4 | |
| SCHEMBL2744853 | 0.80 | KMT2A (0.50) | KDM4EMAPTKMT2AMEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2363393-B1 | Compounds and compositions as hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | claimed |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2012-08-02 | — | — | US | claimed |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | IRM LLC (BM) | 2010-08-05 | — | — | US | claimed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | claimed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | claimed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | claimed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | claimed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | claimed |
| EP-3023097-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | Novartis AG (CH) | 2016-05-25 | — | — | EP | disclosed |
| EP-2363393-B1 | Compounds and compositions as hedgehog pathway modulators | NOVARTIS AG (CH) | 2015-08-12 | — | — | EP | disclosed |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | BUONAMICI SILVIA (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | DORSCH MARION (US) | 2014-07-17 | — | — | US | disclosed |
| US-8778927-B2 | Smoothened antagonism for the treatment of hedgehog pathway-related disorders | NOVARTIS AG (CH) | 2014-07-15 | — | — | US | disclosed |
| WO-2010037715-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | NOVARTIS AG (CH) | 2010-04-08 | — | — | WO | disclosed |
| EP-2162190-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2010-03-17 | — | — | EP | disclosed |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-08-13 | — | — | US | disclosed |
| EP-2021328-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2009-02-11 | — | — | EP | disclosed |
| WO-2008154259-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2008-12-18 | — | — | WO | disclosed |
| WO-2007131201-A2 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | IRM LLC (BM) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025074-A1 | METHODS AND COMPOSITIONS FOR TREATING SOLID TUMORS AND OTHER MALIGNANCIES | MTOR, ULK1, HRAS | KDM4E 1283/4885ALOX15 3879/4885HTT 2914/4885 |
| US-20150209365-A1 | Methods and Compositions for Treating Luekemia | MCL1, ABL1, BCR | KDM4E 2329/4885ALOX15 3665/4885HTT 2856/4885 |
| US-20100197659-A1 | BIPHENYLCARBOXAMIDE DERIVATIVES AS HEDGEHOD PATHWAY MODULATORS | GLI1, SHH, GLI2 | KDM4E 1039/4885ALOX15 4093/4885HTT 1246/4885 |
| US-20090203666-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | KDM4E 1129/4885ALOX15 4367/4885HTT 2560/4885 |
| US-20120196849-A1 | COMPOUNDS AND COMPOSITIONS AS HEDGEHOG PATHWAY MODULATORS | GLI1, SHH, SMO | KDM4E 1129/4885ALOX15 4367/4885HTT 2560/4885 |
| US-20140200217-A1 | SMOOTHENED ANTAGONISM FOR THE TREATMENT OF HEDGEHOG PATHWAY-RELATED DISORDERS | GLI1, SHH, SMO | KDM4E 1460/4885ALOX15 4278/4885HTT 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.